🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Multiple Myeloma ~#ASH20Top10 #mmsm #mmMRD #ASH20 Mike Thompson, MD, PhD, FASCO Table Update: 12/1/20 --Daniel Auclair Ben Derman C. Ola Landgren, M.D. Luciano J Costa Joseph Mikhael Shaji Kumar Nina Shah Phari Raj Chakraborty Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Sigurdur Kristinsson Susan Bal Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Vincent Rajkumar - cc Surviving Myeloma

Your donation towards a histopathology lab at our #Nepal #cancer center could help provide faster care to 5000 patients per year Please consider donating at binayfoundation.org/donations/hist… Shaji Kumar Sid Yadav MD, FACP David Aboulafia, MD Sakti Chakrabarti, MD Axel Grothey Binay Shah, MD, MHA

ce.mayo.edu/hematology-and…

This study is a multi-center phase 2 study of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple #myeloma (SMM). buff.ly/3xjAsly #clinicaltrial #mmsm

IMW21 off to a great start

#IMW2021 opening remarks

Interested in an academic career in #myeloma, #amyloidosis? Apply for an Advanced Fellowship Mayo Myeloma You can develop your clinical expertise in caring for our patients while engaging in exciting and novel clinical and translational research. Apply@ college.mayo.edu/academics/resi…

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: Natalie Callander ow.ly/9Z2o30oEn9T Activated: Apr 30, 2019 #mmsm ECOG-ACRIN Cancer Research Group #NCT03937635 Vincent Rajkumar @mweissmdphd

Ph3 Len +/- Ixa maintenance for MRD+ s/p ASCT -> #EAOnc EAA171 - Optimizing Prolonged Treatment In Myeloma Using MRD assessment (OPTIMUM) [Activation: Jun 1, 2021] clinicaltrials.gov/ct2/show/NCT03… PI= Shaji Kumar #NCT03941860 ECOG-ACRIN Cancer Research Group #mmMRD #mmsm #bmtsm n=510

#Clinicaltrial EAA171/OPTIMUM’s objective is to determine if the addition of ixazomib to lenalidomide improves overall survival for those with previously diagnosed #multiplemyeloma. Learn more here: bit.ly/EAA171OPTIMUM #mmsm cc: Shaji Kumar Mike Thompson, MD, PhD, FASCO Vincent Rajkumar

Preview of the upcoming 5th edition of the World Health Organization Classification of Hematologic Cancers (WHO Blue Book) is now published in Leukemia Journal as two papers. Check it out. #MedTwitter 1/ Lymphoid/Plasma cell neoplasms Open Access link: nature.com/articles/s4137…

2/ Myeloid Neoplasms Open Access link: nature.com/articles/s4137…

3/ Editorial by Dr. Ian Cree. World Health Organization (WHO) IARC https:// Open Access Link: nature.com/articles/s4137…

How should we tackle the challenges of managing relapsed myeloma rdcu.be/cQBS6

NCI myeloma steering committee consensus on relapsed myeloma. Authored by investigators who design & conduct US randomized trials. Blood Cancer Journal Shaji Kumar Noopur Raje Natalie Callander Andrew Yee, MD Suzanne Lentzsch, MD, PhD Philip McCarthy National Cancer Institute #OpenAccess nature.com/articles/s4140…

. This is a very unfair statement. There are 8 sessions. In 7 of the 8 sessions there are women academic colleagues. The program overall has 25 men and 21 women panelists. The myeloma community is very diverse and inclusive. Let’s not divide it.

We are about to start #ASH22 Friday symposium on myeloma. ⁦Clinical Care Options⁩ ⁦International Myeloma Foundation⁩ Philippe Moreau, ⁦Shaji Kumar⁩ ⁦Yi Lin⁩ ⁦Vincent Rajkumar⁩ Jesus San Miguel and ⁦Tom Martin⁩

A well-deserved honor!

NEWS: We are excited to announce that the first patient has been dosed in the Phase 3 study evaluating an investigational BCMA-directed bispecific antibody for patients with relapsed/refractory #MultipleMyeloma. Read more: bit.ly/3yVYkBG. Plasma Cell Pete #mmsm